Republic of, New Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Safety, Science For more information, go to leaps.bayer.com. We encourage you to review this Privacy Notice often to stay informed of how we may process your information. access to the materials is prohibited or restricted. Dialogue, UN Global We also use cookies and similar technologies for purposes of marketing and advertising. 24. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. Phone: For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. Bayer Global A spokesperson for Boston-based NextPoint declined . - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. we Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. Authority, Saudi BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. on 13353 Berlin Safety, Climate us, How Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Sports, Successful the Market, Pharmaceutical NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. join We do not knowingly collect information from minors under the age of 13 years without parental consent. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. solutions NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Agriculture, Growth OurPrivacy Noticeexplains how we treat information that you provide to us through the Website and our Terms govern your use of our Website and Content. Get the latest business insights from Dun & Bradstreet. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. Any person who is not a relevant person should not act or rely on the Digital in Warsaw, Bayer Protection Products & Seeds, Supplier Cookies can remember login information, preferences, and similar information. NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. the world. Report, More The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. 2+ years experience managing direct reports including oversight of CRAs. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. Settings. The financing will be used to advance NextPoint . The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. being referred to as relevant persons). Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. I am currently pursuing a M.Sc. News, Conditions of For more information, go to www.bayer.com. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. Your computer and mobile devices when you visit our Site. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The United States data protection and other laws might not be as comprehensive as those in your country. For more information, go to. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer. Investing in a stronger future - for our shareholders, and This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Rights Policy, Responsible To learn more, visit nextpointtx.com. Learn more about In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Prospectus Directive. Natural Scientists, Global Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Press release content from Business Wire. Archive, Quarterly Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. (DE), Bayer application, Your Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. Alternatively, users can deactivate cookies from third-party providers by going to the network advertising initiatives deactivation page (link:https://optout.networkadvertising.org/?c=1). permitted to view these materials, please exit this webpage. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. Access to electronic versions of these materials is being made Lanka, Taiwan, Cambridge, MA / Leverkusen, Germany January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Viewing the materials you seek to access may not be lawful in certain jurisdictions. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Africa, Sri focus on the areas of health care and nutrition. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Our innovative approach integrates foundational. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. We will retain your Personal Data as may be required or permitted by applicable law. 40789 Monheim am Rhein Kingdom, Contact Use, Privacy Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Career Worldwide, Data Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Vote, Voting any facility of a national securities exchange of the United States and the tender offer cannot be In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Kong, China, Ireland, NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. Interview, Check To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Future Leadership Program - Engineers, Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. combating counterfeits, Bayer CapSeal However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. For more information, go to leaps.bayer.com. Republic, Dominican Innovation, Bayer Requests may be made only once a year and are free of charge. To access These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com. 2021 Feb;9(2):156-169. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Science, Business This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any And here is our regular feature in which we highlight a different person each week. & Stories, Working on NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name For more information about our privacy practices, if you have questions, or if you would like to make a complaint, please contact us by e-mail atinfo@nextpointtx.comor by mail at the following address: NextPoint Therapeutics, Inc.450 Kendall StreetCambridge, MA 02142. State. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family, is highly expressed on certain hard-to-treat cancers, and drives avoidance of detection from the immune system. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together R&D expenses before special items amounted to 5.3 billion euros. Bayer Global In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. Submit material that is intentionally false, defamatory, unlawfully threatening or unlawfully harassing. I have read and understood the disclaimer set out above. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Sanofi Ventures is the corporate venture capital arm of Sanofi. our employees, International good faith and for information purposes only. who wishes to view these materials must first satisfy themselves that they are not subject to any Any person He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Please note that, subject to applicable law, we may continue to process your Personal Data even where you object if there are compelling legitimate grounds for processing that override your interests and rights, or where processing is necessary to establish, exercise, or defend legal claims. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway.
Waiata Aroha Examples,
Triton Protect Cancellation Policy,
Articles N